Wed, May 14, 8:07 PM (66 days ago)
### ImmuCell Corporation (ICCC) Q1 2025 Financial Summary **Company Overview:** ImmuCell Corporation (ICCC) is an animal health company focused on improving the health and productivity of dairy and beef cattle. Their primary products include the First Defense® line, which prevents scours in newborn calves, and Re-Tain®, a treatment for subclinical mastitis in lactating dairy cows. **Financial Performance (Q1 2025 vs. Q1 2024):** - **Revenue:** $8,067,174 (up 11% from $7,257,577). - **Gross Margin:** $3,353,972 (42% of revenue, up from $2,295,359 or 32% of revenue). - **Operating Expenses:** $2,236,348 (down from $2,595,411). - **Net Income:** $1,446,983 (up from a loss of $437,868). - **Earnings per Share (EPS):** $0.16 (up from a loss of $0.06). **Cash Flow:** - **Operating Cash Flow:** $1,573,836 (up from $418,505). - **Investing Cash Flow:** -$329,050 (down from -$70,356). - **Financing Cash Flow:** -$403,647 (down from -$366,543). **Balance Sheet Highlights:** - **Cash and Cash Equivalents:** $4,599,371 (up from $3,758,232). - **Total Assets:** $45,621,579 (up from $45,100,477). - **Total Liabilities:** $16,627,735 (up from $17,582,290). - **Stockholders' Equity:** $28,993,844 (up from $27,518,187). **Key Metrics:** - **Current Ratio:** 1.82 (up from 1.72). - **Debt-to-Equity Ratio:** 0.57 (down from 0.64). - **Gross Margin:** 42% (up from 32%). **Operational Highlights:** - **Product Sales:** Dominated by the First Defense® line, which accounted for 99% of total sales. - **Geographical Sales:** 89% from the United States, 11% from other regions. - **Production:** Increased production capacity and remediated contamination events, leading to higher output and improved yields. **Future Outlook:** - **Re-Tain® Development:** Continues to pursue FDA approval and market launch, with ongoing regulatory and manufacturing challenges. - **First Defense®:** Focus on maintaining supply and expanding market share. - **Financial Strategy:** Continued use of ATM offerings to raise capital and manage liquidity. **Risks and Uncertainties:** - **Regulatory Risks:** Dependence on FDA approval for Re-Tain®. - **Market Risks:** Competition and market acceptance of new products. - **Operational Risks:** Supply chain disruptions and production challenges. **Conclusion:** ImmuCell Corporation showed strong financial performance in Q1 2025, driven by increased sales and improved operational efficiency. The company continues to invest in product development and regulatory approvals, with a focus on maintaining liquidity and managing risks.